Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Panel Discussion

<< Previous

Bullboard Posts

Next >>

Comment by lonc17on Apr 15, 2024 1:24pm

68 Views

Post# 35989723

RE:Panel Discussion

There is a noticeable correlation between Matt's appearances in public and a decline in ONC's shareprice.

He has lilttle credibility left after over promising and under delivering for half a decade.

Lately his enthusiasm feels forced and he can be difficult to listen to.

ONC would be far better served with a new CEO who can deliver something of substance.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023